In the latest trading session,, 0.5 million Revolution Medicines Inc (NASDAQ:RVMD) shares changed hands as the company’s beta touched 1.11. With the company’s most recent per share price at $41.29 changing hands around $2.52 or 6.50% at last look, the market valuation stands at $7.68B. RVMD’s current price is a discount, trading about -51.13% off its 52-week high of $62.40. The share price had its 52-week low at $29.17, which suggests the last value was 29.35% up since then. When we look at Revolution Medicines Inc’s average trading volume, we note the 10-day average is 1.47 million shares, with the 3-month average coming to 1.52 million.
Analysts gave the Revolution Medicines Inc (RVMD) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.08. If we narrow down to specifics, the data shows that 1 out of 13 analysts rate the stock as a Sell, with a further 1 assigning it an Overweight rating. Of the remaining, 0 recommended RVMD as a Hold, 11 felt it is a Buy and 0 rated the stock as Underweight. Revolution Medicines Inc’s EPS for the current quarter is expected to be -1.06.
Revolution Medicines Inc (NASDAQ:RVMD) trade information
Instantly RVMD is in green as seen in intraday trades today. With action 12.94%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -5.60%, with the 5-day performance at 12.94% in the green. However, in the 30-day time frame, Revolution Medicines Inc (NASDAQ:RVMD) is 8.37% up. Looking at the short shares, we see there were 16.43 million shares sold at short interest cover period of 8.89 days.
The consensus price target for the stock as assigned by Wall Street analysts is 67, meaning bulls need an upside of 38.37% from its recent market value. According to analyst projections, RVMD’s forecast low is 62 with 71 as the target high. To hit the forecast high, the stock’s price needs a -71.95% plunge from its current level, while the stock would need to soar -50.16% for it to hit the projected low.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -27.80%. The 2025 estimates are for Revolution Medicines Inc earnings to decrease by -28.14%, but the outlook for the next 5-year period is at -4.28% per year.
RVMD Dividends
Revolution Medicines Inc is expected to release its next quarterly earnings report on 2025-Feb-25.
Revolution Medicines Inc (NASDAQ:RVMD)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.01% of Revolution Medicines Inc shares while 108.18% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 110.40%. There are 108.18% institutions holding the Revolution Medicines Inc stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-06-30, the company held 8.7066% of the shares, roughly 14.38 million RVMD shares worth $558.02 million.
WELLINGTON MANAGEMENT GROUP LLP holds the second largest percentage of outstanding shares, with 8.2718% or 13.66 million shares worth $530.15 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . With 5.45 shares estimated at $225.55 million under it, the former controlled 2.93% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 2.41% of the shares, roughly 4.48 shares worth around $185.23 million.
